Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Systematic review of non-icans neurological toxicities associated with BCMA and GPRC5D-directed CAR-T cell therapy in plasma cell dyscrasia

Manpreet Saini, FNU Deeksha, Aditya Jandial et al. Nov 03, 2025 pp. 2802-2802 10.1182/blood-2025-2802

Abstract Introduction CAR T-cell therapy targeting BCMA and GPRC5D has demonstrated remarkable efficacy in relapsed/refr...

Novel In Vivo CAR platform for autoimmune disease therapy

Claudia Lee, Angie Chang, Christian Rimbau et al. Nov 03, 2025 pp. 4131-4131 10.1182/blood-2025-4131

Abstract Background: Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS)...

Chidamide in combination with brentuximab vedotin for CD30+ peripheral T-cell lymphoma in patients ineligible for chemotherapy: a prospective phase II study

Changju Qu, Nana Ping, Danqing Kong et al. Nov 03, 2025 pp. 7167-7167 10.1182/blood-2025-7167

Abstract Background: The prognosis for patients with peripheral T-cell lymphoma (PTCL) remains extremely poor, posing significant challenges...

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Syed Hussain, Laith Hamed, Anna Shamis et al. Nov 03, 2025 pp. 6370-6370 10.1182/blood-2025-6370

Abstract Background: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are BCMA-directed CAR-T...

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang et al. Nov 03, 2025 pp. 5466-5466 10.1182/blood-2025-5466

Abstract Introduction: Brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, has demonstrated effectiveness in CD30-positive lymph...

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

Naval Daver, Andrew Sochacki, Monzr M. Al Malki et al. Nov 03, 2025 pp. 5194-5194 10.1182/blood-2025-5194

Abstract Background and Significance: Acute Myeloid Leukemia (AML) is the most common adult acute leukemia and is an aggressive hematologic...

Restraint of TGF-β signaling by SMAD7 is necessary for the maturation of hematopoietic stem cells in the mouse embryo

Laura Bennett, Wenbao Yu, Hyun Hyung An et al. Nov 03, 2025 pp. 4929-4929 10.1182/blood-2025-4929

Abstract Hematopoietic stem and progenitor cells (HSPCs) in the mouse embryo arise from a subset of arterial hemogenic endothelial cells whi...

Barriers to continuity of care and adult practice retention among adolescents and young adults with sickle cell disease

Yogindra Persaud, Paul Lavoie, Rana Cooper et al. Nov 03, 2025 pp. 4379-4379 10.1182/blood-2025-4379

Abstract Introduction For adolescents and young adults (AYA) with sickle cell disease (SCD), successful pediatric to adult care transition i...

Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML

Sarah Skuli, Jayakumar Vadakekolathu, Elena Fenu et al. Nov 03, 2025 pp. 1734-1734 10.1182/blood-2025-1734

Abstract Introduction Acute myeloid leukemia (AML) with mutations in TP53 (TP53-Mut AML) is a high-risk disease with a dismal prognosis. How...

Luspatercept in patients with hematological diseases who have delayed erythroid recovery after allogeneic hematopoietic stem cell transplantation.

Bingqian Jiang, Jian Yu, Yanmin Zhao et al. Nov 03, 2025 pp. 2426-2426 10.1182/blood-2025-2426

Abstract Introduction Delayed erythroid recovery after hematopoietic stem cell transplantation (HSCT) is a common and concerning complicatio...

Soluble immune modulators in the bone marrow microenvironment predict long-term survival in pediatric de novo AML: An olink-based proteomic and transcriptomic study

Yongping Zhang, Qi Ji, Shaoyan Hu Nov 03, 2025 pp. 5289-5289 10.1182/blood-2025-5289

Abstract Background The bone marrow (BM) microenvironment plays a critical role in acute myeloid leukemia (AML) by shaping immune surveillan...

TP53 mutation promotes diffuse large B-cell lymphoma progression via mediating lactylation of ATP5E at Lys44

Linquan Zhan, Chenyang Jiang, Tiange Lu et al. Nov 03, 2025 pp. 5037-5037 10.1182/blood-2025-5037

Abstract Lactate has recently been shown to play an important role in remodeling the tumor microenvironment and regulating energy metabolism...

Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study

Thomas Silfverberg, Honar Cherif, Emma Smitt et al. Nov 03, 2025 pp. 5811-5811 10.1182/blood-2025-5811

Abstract Introduction Despite the introduction of numerous novel agents, high-dose melphalan (HDM) followed by autologous hematopoietic stem...

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

Lauren Merz, Sabine Allam, Sungjae Kim et al. Nov 03, 2025 pp. 4578-4578 10.1182/blood-2025-4578

Abstract Introduction: There is a 3x higher prevalence of MGUS in people identifying as Black. However, race is a social construct making th...

Autonomous BCR signaling and the CARD11 L251P mutation as alternative oncogenic drivers induce identical gene expression profiles in genetically engineered ABC-DLBCL models

Janneke Eken, Edwin Quinten, Cornelis van Bergen et al. Nov 03, 2025 pp. 1484-1484 10.1182/blood-2025-1484

Abstract Diffuse large B-cell lymphoma of activated B-cell type (ABC-DLBCL) is characterized by constitutive NF-kB activation through activa...

Liver-targeted delivery of bioengineered induced tregs via nanoparticles prevents and treats acute gvhd

Hyesun Hyun, Sonia Laurie, Danny Bruce et al. Nov 03, 2025 pp. 5861-5861 10.1182/blood-2025-5861

Abstract Induced regulatory T cell (iTregs) therapy holds promise for graft-versus-host disease (GvHD), but clinical translation has been li...

Impact of slim-CRAB criteria on treatment initiation in newly diagnosed multiple myeloma in the veteran health administration

Mengmeng Ji, Mahta Salehi, Mei Wang et al. Nov 03, 2025 pp. 6378-6378 10.1182/blood-2025-6378

Abstract Introduction In 2014, the International Myeloma Working Group (IMWG) modified the diagnostic criteria for active multiple myeloma (...

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT:  a study from the acute leukemia working party of the EBMT

Mingyang Wang, Allain Thibeault Ferhat, Depei Wu et al. Nov 03, 2025 pp. 6041-6041 10.1182/blood-2025-6041

Abstract Background While autologous hematopoietic cell transplantation (auto-HCT) is a feasible post-remission strategy for patients with a...

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Keiji Nogami, Nobuaki Suzuki, Chiai Nagae et al. Nov 03, 2025 pp. 303-303 10.1182/blood-2025-303

Abstract Background: Immune tolerance induction (ITI) therapy is recommended to eradicate factor (F)VIII inhibitors in people with hemophili...

Mortality associated with warm autoimmune hemolytic anemia among Medicare beneficiaries

Louis Jackson, Maryia Zhdanava, Jacqueline Pesa et al. Nov 03, 2025 pp. 2694-2694 10.1182/blood-2025-2694

Abstract INTRODUCTION: Warm autoimmune hemolytic anemia (wAIHA) is a rare, autoimmune-mediated hematologic disorder associated with signific...

Exploring molecular heterogeneity and clonal evolution in chronic myelomonocytic leukemia via single-cell transcriptome sequencing

Jie Zhou, Yuyuan Huang, Hao Wu et al. Nov 03, 2025 pp. 6763-6763 10.1182/blood-2025-6763

Abstract Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that combines clinical and biologic...

Deciphering the bone marrow inflammatory cytokine network in AML prognosis and immune evasion: A focus on the IL-1A-CCL3/4 axis as a novel therapeutic target

Wang Shuqing, Jian Li Nov 03, 2025 pp. 1456-1456 10.1182/blood-2025-1456

Abstract Background: Acute Myeloid Leukemia (AML) is characterized by a profoundly dysregulated bone marrow microenvironment (BME) that fost...

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Gao Yan, Huijing Wu, Qingyuan Zhang et al. Nov 03, 2025 pp. 776-776 10.1182/blood-2025-776

Abstract Background Outcomes for patients with relapsed/refractory (R/R) peripheral T-cell lymphomas (R/R-PTCLs) are poor. Single agent over...

Identification of novel, potent, and selective JAK2V617F inhibitors

Fazal Hadi, Peter Linders, Kimberly Ornell et al. Nov 03, 2025 pp. 4326-4326 10.1182/blood-2025-4326

Abstract The predominant oncogenic variant driving myeloproliferative neoplasms (MPNs) is the JAK2V617F substitution, where valine is replac...

Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Uma Borate, Jayanshu Jain, Ying Huang et al. Nov 03, 2025 pp. 3427-3427 10.1182/blood-2025-3427

Abstract Introduction: REV is an oral targeted menin inhibitor approved for treatment of R/R acute leukemia with KMT2Ar that also has demons...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page